β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study

References

• Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–898. doi:10.1126/science.aaf3934
   PubMed Web of Science ®Google Scholar
• Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. β2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683–693. doi:10.1002/ana.25341
   PubMed Web of Science ®Google Scholar
• Hopfner F, Höglinger GU, Kuhlenbäumer G, et al. β-adrenoreceptors and the risk of Parkinson’s disease. Lancet Neurol. 2020;19(3):247–254.
   PubMed Web of Science ®Google Scholar
• Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W. β2-adrenoceptor agonists and antagonists and risk of Parkinson’s disease. Mov Disord off J Mov Disord Soc. 2018;33(9):1465–1471. doi:10.1002/mds.108
   PubMed Web of Science ®Google Scholar
• Chen W, Sadatsafavi M, Tavakoli H, Samii A, Etminan M. Effects of β2-adrenergic agonists on risk of Parkinson’s disease in COPD: a population-based study. Pharmacotherapy. 2020;40(5):408–415. doi:10.1002/phar.2383
   PubMed Web of Science ®Google Scholar
• Marras C, Pequeno P, Austin PC, et al. Beta agonists and progression of Parkinson’s disease in older adults: a retrospective cohort study. Mov Disord off J Mov Disord Soc. 2020;35(7):1275–1277. doi:10.1002/mds.28085
   PubMed Web of Science ®Google Scholar
• Hopfner F, Wod M, Höglinger GU, et al. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology. 2019;93(2):e135–e142. doi:10.1212/WNL.0000000000007694
   PubMed Web of Science ®Google Scholar
• Giorgianni F, Ernst P, Dell’Aniello S, Suissa S, Renoux C. β2-agonists and the incidence of Parkinson disease. Am J Epidemiol. 2020;189(8):801–810. doi:10.1093/aje/kwaa012
   PubMed Web of Science ®Google Scholar
• de Germay S, Conte C, Rascol O, Montastruc JL, Lapeyre-Mestre M. β-adrenoceptor drugs and Parkinson’s Disease: a nationwide nested case-control study. CNS Drugs. 2020;34(7):763–772. doi:10.1007/s40263-020-00736-2
   PubMed Web of Science ®Google Scholar
• Belvisi D, Pellicciari R, Fabbrini A, et al. Risk factors of Parkinson disease: simultaneous assessment, interactions, and etiologic subtypes. Neurology. 2020;95(18):e2500–e2508. doi:10.1212/WNL.0000000000010813
   PubMed Web of Science ®Google Scholar
• Courtois É, Nguyen TTH, Fournier A, et al. Identifying protective drugs for Parkinson’s disease in health-care databases using machine learning. Mov Disord off J Mov Disord Soc. 2022;37:2376–2385. doi:10.1002/mds.29205
   PubMed Web of Science ®Google Scholar
• Magistrelli L, Comi C. Beta2-adrenoceptor agonists in Parkinson’s disease and other synucleinopathies. J Neuroimmune Pharmacol off J Soc NeuroImmune Pharmacol. 2020;15(1):74–81. doi:10.1007/s11481-018-09831-0
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192. doi:10.1038/nri2254
   PubMed Web of Science ®Google Scholar
• Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52(3):276–284. doi:10.1002/ana.10277
   PubMed Web of Science ®Google Scholar
• Yawn BP, Mintz ML, Doherty DE. GOLD in practice: chronic obstructive pulmonary disease treatment and management in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289–299. doi:10.2147/COPD.S222664
   PubMed Web of Science ®Google Scholar
• Hentilä E, Tiihonen M, Taipale H, Hartikainen S, Tolppanen AM. Incidence of antidepressant use among community dwellers with and without Parkinson’s disease - a nationwide cohort study. BMC Geriatr. 2021;21(1):202–206. doi:10.1186/s12877-021-02145-6
   PubMed Web of Science ®Google Scholar
• Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014;20(8):840–844. doi:10.1016/j.parkreldis.2014.04.019
   PubMed Web of Science ®Google Scholar
• Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566–576. doi:10.1212/WNL.0000000000002350
   PubMed Web of Science ®Google Scholar
• Paakinaho A, Karttunen N, Koponen M, et al. Incidence of muscle relaxant use in relation to diagnosis of Parkinson’s disease. Int J Clin Pharm. 2020;42(2):336–340. doi:10.1007/s11096-020-01002-7
   PubMed Web of Science ®Google Scholar
• WHOCC. Definition and general considerations; 2022. Available from: https://www.whocc.no/ddd/definition_and_general_considera/. Accessed May 13, 2022.
   Google Scholar
• Cheng CM, Wu YH, Tsai SJ, et al. Risk of developing Parkinson’s disease among patients with asthma: a nationwide longitudinal study. Allergy. 2015;70(12):1605–1612. doi:10.1111/all.12758
   PubMed Web of Science ®Google Scholar
• GINA & GOLD. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) 2015; 2015. Available from: https://goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/. Accessed May 19, 2022.
   Google Scholar
• Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy. 2011;2011:1–10. doi:10.1155/2011/861926
   Google Scholar
• Nielsen M, Bårnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome--a systematic review. Int J Chron Obstruct Pulmon Dis. 2015;10:1443–1454. doi:10.2147/COPD.S85363
   PubMed Web of Science ®Google Scholar
• Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385(9971):899–909. doi:10.1016/S0140-6736(14)60446-3
   PubMed Web of Science ®Google Scholar
• Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Eur Respir J. 2000;15(3):470–477. doi:10.1034/j.1399-3003.2000.15.08.x
   PubMed Web of Science ®Google Scholar
• Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013;41(3):716–726. doi:10.1183/09031936.00073312
   PubMed Web of Science ®Google Scholar
• Koskela HO, Hyva¨rinen L, Brannan JD, Chan HK, Anderson SD. Responsiveness to three bronchial provocation tests in patients with asthma. Chest. 2003;124(6):2171–2177. doi:10.1378/chest.124.6.2171
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Harju T, Kilpeläinen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol. 2015;116(4):291–307. doi:10.1111/bcpt.12366
   PubMed Web of Science ®Google Scholar
• Kainu A, Rouhos A, Sovijärvi A, Lindqvist A, Sarna S, Lundbäck B. COPD in Helsinki, Finland: socioeconomic status based on occupation has an important impact on prevalence. Scand J Public Health. 2013;41(6):570–578. doi:10.1177/1403494813484554
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF Jr, Pace W, Schatz M. Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program. JAMA. 2020;324(22):2301–2317. doi:10.1001/jama.2020.21974
   PubMed Web of Science ®Google Scholar